Yong A S, Goldman J M
Bone Marrow Transplant. 1999 Apr;23(8):827-8. doi: 10.1038/sj.bmt.1701729.
Allogeneic bone marrow transplantation (BMT) is the treatment of choice for patients with chronic myeloid leukaemia (CML) who are relatively young and have suitable donors. Relapse is rare more than 5 years after allografting. We describe a patient who relapsed with myeloid blast transformation 14 years after allografting. This case suggests that leukaemia stem cells may on occasion remain quiescent for long periods and emphasises the importance of long-term follow-up after transplantation for CML.
异基因骨髓移植(BMT)是相对年轻且有合适供体的慢性髓性白血病(CML)患者的首选治疗方法。移植后5年以上复发罕见。我们描述了一名患者,其在移植后14年因髓系原始细胞转化而复发。该病例表明白血病干细胞有时可能长期处于静止状态,并强调了CML移植后长期随访的重要性。